UBS Group
SKYE icon

UBS Group’s Skye Bioscience SKYE Stock Holding History

UBS Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.1K Buy
45,762
+32,476
+244% +$26.5K ﹤0.01% 7731
2025
Q4 		$9.96K Sell
13,286
-16,704
-56% -$24.4K ﹤0.01% 8252
2025
Q3 		$118K Sell
29,990
-11,533
-28% -$43.6K ﹤0.01% 7005
2025
Q2 		$174K Sell
41,523
-110,065
-73% -$228K ﹤0.01% 6815
2025
Q1 		$241K Buy
151,588
+92,012
+154% +$251K ﹤0.01% 6417
2024
Q4 		$169K Buy
59,576
+33,619
+130% +$140K ﹤0.01% 6558
2024
Q3 		$101K Buy
25,957
+20,707
+394% +$116K ﹤0.01% 6357
2024
Q2 		$42.1K Buy
+5,250
New +$62.3K ﹤0.01% 6828

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group's SKYE Position: Q1 2026 in Review

UBS Group increased its Skye Bioscience (SKYE) stake by 244% in Q1 2026, buying an estimated $26.5K and bringing the position to 45,762 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7731.

UBS Group first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $241K in Q1 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • UBS Group held 45,762 shares of Skye Bioscience worth $28.1K as of Q1 2026.
  • UBS Group bought 32,476 Skye Bioscience shares in Q1 2026, an estimated $26.5K.
  • Skye Bioscience made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7731 holding.
  • UBS Group first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • UBS Group's Skye Bioscience position peaked at $241K in Q1 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.